FSD Pharma [HUGE] vs Intra-Cellular [ITCI] Detailed Stock Comparison

FSD Pharma Inc.

NASDAQ
Loading...

Intra-Cellular Therapies Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: FSD Pharma Inc. wins in 6 metrics, Intra-Cellular Therapies Inc. wins in 8 metrics, with 0 ties. Intra-Cellular Therapies Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric FSD Pharma Inc. Intra-Cellular Therapies Inc. Better
P/E Ratio (TTM) -0.18 -183.15 FSD Pharma Inc.
Price-to-Book Ratio 0.01 12.20 FSD Pharma Inc.
Debt-to-Equity Ratio 6.13 1.48 Intra-Cellular Therapies Inc.
PEG Ratio -0.75 507.19 Intra-Cellular Therapies Inc.
EV/EBITDA -0.03 -112.19 FSD Pharma Inc.
Profit Margin (TTM) 0.00% -10.97% FSD Pharma Inc.
Operating Margin (TTM) 0.00% -14.66% FSD Pharma Inc.
Return on Equity -63.89% -8.58% Intra-Cellular Therapies Inc.
Return on Assets (TTM) -36.47% -6.96% Intra-Cellular Therapies Inc.
Free Cash Flow (TTM) $-10.83M $-73.50M FSD Pharma Inc.
1-Year Return -92.53% 92.68% Intra-Cellular Therapies Inc.
Price-to-Sales Ratio (TTM) N/A 20.63 N/A
Enterprise Value $287,159 $13.04B Intra-Cellular Therapies Inc.
EV/Revenue Ratio N/A 19.15 N/A
Gross Profit Margin (TTM) N/A 89.76% N/A
Revenue per Share (TTM) $0 $7 Intra-Cellular Therapies Inc.
Earnings per Share (Diluted) $-16.25 $-0.73 Intra-Cellular Therapies Inc.
Beta (Stock Volatility) N/A 0.46 N/A

FSD Pharma Inc. vs Intra-Cellular Therapies Inc. Stock Performance Analysis

Loading Price Chart...

HUGE
ITCI

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
FSD Pharma Inc.12.29%N/AN/AN/AN/AN/A
Intra-Cellular Therapies Inc.0.00%N/AN/AN/AN/AN/A

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
FSD Pharma Inc.-92.53%-94.20%-98.33%-99.52%-99.52%-99.52%
Intra-Cellular Therapies Inc.92.68%104.13%700.67%449.92%632.61%632.61%

Performance & Financial Health Analysis: FSD Pharma Inc. vs Intra-Cellular Therapies Inc.

MetricHUGEITCI
Market Information
Market Cap iN/A$14.05B
Market Cap CategoryN/ALarge cap
10 Day Avg. Volume i82,6632,749,368
90 Day Avg. Volume i62,7792,309,509
Last Close$5.39$131.87
52 Week Range$3.50 - $97.50$64.09 - $131.98
% from 52W High-94.47%-0.08%
All-Time High$11,432.16 (Sep 10, 2018)$131.98 (Mar 31, 2025)
% from All-Time High-99.95%-0.08%
Growth Metrics
Quarterly Revenue GrowthN/A0.51%
Quarterly Earnings GrowthN/A0.51%
Financial Health
Profit Margin (TTM) i0.00%-0.11%
Operating Margin (TTM) i0.00%-0.15%
Return on Equity (TTM) i-0.64%-0.09%
Debt to Equity (MRQ) i6.131.48
Cash & Liquidity
Book Value per Share (MRQ)$17.09$10.81
Cash per Share (MRQ)$5.19$9.42
Operating Cash Flow (TTM) i$-5,144,110$-73,177,000
Levered Free Cash Flow (TTM) i$-10,054,595$-63,549,624
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: FSD Pharma Inc. vs Intra-Cellular Therapies Inc.

MetricHUGE (Mar 31, 2025)ITCI (May 17, 2025)
Price Ratios
P/E Ratio (TTM) i-0.18-183.15
Forward P/E i-0.75507.19
PEG Ratio i-0.75507.19
Price to Sales (TTM) iN/A20.63
Price to Book (MRQ) i0.0112.20
Market Capitalization
Market Capitalization i$66,671$14.05B
Enterprise Value i$287,159$13.04B
Enterprise Value Metrics
Enterprise to Revenue iN/A19.15
Enterprise to EBITDA i-0.03-112.19
Risk & Other Metrics
Beta iN/A0.46
Book Value per Share (MRQ) i$17.09$10.81

Financial Statements Comparison: FSD Pharma Inc. vs Intra-Cellular Therapies Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricHUGE (2023)ITCI (2024)
Revenue/Sales i0680.50M
Cost of Goods Sold iN/A56.96M
COGS % of Revenue i-8.4%
Gross Profit iN/A623.54M
Gross Margin i-91.6%
Research & Development i3.86M236.12M
Operating Income (EBIT) i-19.57M-116.72M
Operating Margin i--17.2%
EBITDA i-11.34M-116.21M
EBITDA Margin i--17.1%
Pre-Tax Income i-18.23M-74.20M
Pre-Tax Income % of Revenue i--10.9%
Income Tax iN/A473,000
Income Tax % of Revenue i-0.1%
Net Income (Profit) i-18.23M-74.68M
Profit Margin i--11.0%

Balance Sheet & Liquidity Metrics

MetricHUGE (2023)ITCI (2024)
Cash & Equivalents i2.76M306.95M
Total Current Assets i11.09M1.31B
Total Current Assets % of Revenue i-192.1%
Total Current Liabilities i4.57M205.70M
Total Current Liabilities % of Revenue i-30.2%
Long-Term Debt i012.75M
Long-Term Debt % of Revenue i-1.9%
Total Shareholders Equity i12.91M1.15B
Retained Earnings i-157.91M-1.69B
Retained Earnings % of Revenue i--248.6%
Property, Plant & Equipment i120,42114.90M

Cash Flow Statement Comparison

MetricHUGE (2023)ITCI (2024)
Operating Cash Flow i-17.53M-63.27M
Operating Cash Flow % of Revenue i--9.3%
Capital Expenditures i0-322,000
Free Cash Flow i-10.83M-73.50M
FCF Margin i--10.8%
Debt Repayment i-189,054N/A
Common Stock Repurchase i-2.96MN/A

Short Interest & Institutional Ownership Analysis

MetricHUGEITCI
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i605,796106.24M
Float Shares i600,696104.82M
% Held by Insiders i9.74%2.48%
% Held by Institutions i2.69%96.45%
% Held by Public i87.57%1.07%

Dividend Analysis & Yield Comparison: FSD Pharma Inc. vs Intra-Cellular Therapies Inc.

MetricHUGEITCI
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A